1. Home
  2. LEGN vs FLS Comparison

LEGN vs FLS Comparison

Compare LEGN & FLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • LEGN
  • FLS
  • Stock Information
  • Founded
  • LEGN 2014
  • FLS 1790
  • Country
  • LEGN United States
  • FLS United States
  • Employees
  • LEGN N/A
  • FLS N/A
  • Industry
  • LEGN Biotechnology: Pharmaceutical Preparations
  • FLS Fluid Controls
  • Sector
  • LEGN Health Care
  • FLS Industrials
  • Exchange
  • LEGN Nasdaq
  • FLS Nasdaq
  • Market Cap
  • LEGN 7.0B
  • FLS 8.3B
  • IPO Year
  • LEGN 2020
  • FLS N/A
  • Fundamental
  • Price
  • LEGN $33.91
  • FLS $48.73
  • Analyst Decision
  • LEGN Strong Buy
  • FLS Strong Buy
  • Analyst Count
  • LEGN 13
  • FLS 10
  • Target Price
  • LEGN $79.17
  • FLS $68.60
  • AVG Volume (30 Days)
  • LEGN 1.1M
  • FLS 1.8M
  • Earning Date
  • LEGN 03-11-2025
  • FLS 04-28-2025
  • Dividend Yield
  • LEGN N/A
  • FLS 1.72%
  • EPS Growth
  • LEGN N/A
  • FLS 50.70
  • EPS
  • LEGN N/A
  • FLS 2.14
  • Revenue
  • LEGN $627,241,000.00
  • FLS $4,557,806,000.00
  • Revenue This Year
  • LEGN $66.60
  • FLS $6.96
  • Revenue Next Year
  • LEGN $49.28
  • FLS $4.72
  • P/E Ratio
  • LEGN N/A
  • FLS $22.79
  • Revenue Growth
  • LEGN 119.97
  • FLS 5.49
  • 52 Week Low
  • LEGN $30.17
  • FLS $43.66
  • 52 Week High
  • LEGN $60.87
  • FLS $65.08
  • Technical
  • Relative Strength Index (RSI)
  • LEGN 39.53
  • FLS 37.40
  • Support Level
  • LEGN $34.00
  • FLS $49.68
  • Resistance Level
  • LEGN $36.20
  • FLS $53.53
  • Average True Range (ATR)
  • LEGN 1.39
  • FLS 1.41
  • MACD
  • LEGN -0.33
  • FLS 0.30
  • Stochastic Oscillator
  • LEGN 17.81
  • FLS 26.04

About LEGN Legend Biotech Corporation

Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's lead product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.

About FLS Flowserve Corporation

Flowserve Corp is a manufacturer and aftermarket service provider of comprehensive flow control systems. It develops precision-engineered flow control equipment to monitor movement and protect customers' materials and processes. It offers an extensive range of pumps, valves, seals, and services for several industries, including oil and gas, chemical, power generation, and water management. In addition, Flowserve has a network of Quick Response Centers to provide aftermarket equipment services. The aftermarket services help customers with installation, diagnostics, repair, and retrofitting. Sales are roughly split across many regions, with North America and Europe contributing the majority of total revenue.

Share on Social Networks: